Agios Pharmaceuticals Inc (AGIO)
45.61
-2.44
(-5.08%)
USD |
NASDAQ |
Sep 27, 16:00
45.57
-0.04
(-0.09%)
After-Hours: 20:00
Agios Pharmaceuticals Research and Development Expense (Annual): 295.53M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 295.53M |
| December 31, 2022 | 279.91M |
| December 31, 2021 | 256.97M |
| December 31, 2020 | 220.81M |
| December 31, 2019 | 214.26M |
| December 31, 2018 | 341.32M |
| December 31, 2017 | 292.68M |
| Date | Value |
|---|---|
| December 31, 2016 | 220.16M |
| December 31, 2015 | 141.83M |
| December 31, 2014 | 100.37M |
| December 31, 2013 | 54.50M |
| December 31, 2012 | 41.04M |
| December 31, 2011 | 31.25M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
214.26M
Minimum
2019
295.53M
Maximum
2023
253.50M
Average
256.97M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Pfizer Inc | 10.68B |
| Regeneron Pharmaceuticals Inc | 4.439B |
| Ligand Pharmaceuticals Inc | 24.54M |
| ADMA Biologics Inc | 3.30M |
| AnaptysBio Inc | 132.28M |